BOLT BIOTHERAPEUTICS INC (BOLT)

US0977021049 - Common Stock

1.4  +0.18 (+14.75%)

After market: 1.34 -0.06 (-4.29%)

Fundamental Rating

3

BOLT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 592 industry peers in the Biotechnology industry. The financial health of BOLT is average, but there are quite some concerns on its profitability. BOLT is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

BOLT had negative earnings in the past year.
BOLT had a negative operating cash flow in the past year.
BOLT had negative earnings in each of the past 5 years.
In the past 5 years BOLT always reported negative operating cash flow.

1.2 Ratios

BOLT has a Return On Assets (-43.31%) which is comparable to the rest of the industry.
With a Return On Equity value of -61.38%, BOLT perfoms like the industry average, outperforming 59.52% of the companies in the same industry.
Industry RankSector Rank
ROA -43.31%
ROE -61.38%
ROIC N/A
ROA(3y)-38.01%
ROA(5y)-61.52%
ROE(3y)-50.72%
ROE(5y)-4098.34%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BOLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

BOLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BOLT has been increased compared to 1 year ago.
Compared to 5 years ago, BOLT has more shares outstanding
There is no outstanding debt for BOLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -3.40, we must say that BOLT is in the distress zone and has some risk of bankruptcy.
BOLT has a Altman-Z score (-3.40) which is in line with its industry peers.
BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.4
ROIC/WACCN/A
WACC8.98%

2.3 Liquidity

BOLT has a Current Ratio of 5.17. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.17, BOLT is in line with its industry, outperforming 54.42% of the companies in the same industry.
BOLT has a Quick Ratio of 5.17. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
BOLT has a Quick ratio of 5.17. This is comparable to the rest of the industry: BOLT outperforms 54.93% of its industry peers.
Industry RankSector Rank
Current Ratio 5.17
Quick Ratio 5.17

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.46% over the past year.
BOLT shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.74%.
Measured over the past years, BOLT shows a very strong growth in Revenue. The Revenue has been growing by 224.73% on average per year.
EPS 1Y (TTM)22.46%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q11.32%
Revenue 1Y (TTM)37.74%
Revenue growth 3Y224.73%
Revenue growth 5YN/A
Revenue growth Q2Q48.16%

3.2 Future

BOLT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.50% yearly.
Based on estimates for the next years, BOLT will show a very strong growth in Revenue. The Revenue will grow by 47.98% on average per year.
EPS Next Y8.59%
EPS Next 2Y12.11%
EPS Next 3Y27.04%
EPS Next 5Y6.5%
Revenue Next Year-32.83%
Revenue Next 2Y-36.58%
Revenue Next 3Y114.6%
Revenue Next 5Y47.98%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

BOLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BOLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BOLT's earnings are expected to grow with 27.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.11%
EPS Next 3Y27.04%

0

5. Dividend

5.1 Amount

No dividends for BOLT!.
Industry RankSector Rank
Dividend Yield N/A

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (3/28/2024, 8:00:02 PM)

After market: 1.34 -0.06 (-4.29%)

1.4

+0.18 (+14.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap53.38M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.31%
ROE -61.38%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.17
Quick Ratio 5.17
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)22.46%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y8.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)37.74%
Revenue growth 3Y224.73%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y